Türker Sonay, Güneri Sema, Akdeniz Bahri, Ozcan Mehmet Ali, Baris Nezihi, Badak Ozer, Kirimli Onder, Yüksel Faize
Department of Cardiology, Dokuz Eylül University School of Medicine, Izmir, Turkey.
Am J Cardiol. 2006 Jan 15;97(2):198-202. doi: 10.1016/j.amjcard.2005.08.024. Epub 2005 Nov 21.
CD40-CD40 ligand interaction is involved in the inflammatory pathogenesis of atherosclerosis but clinical data about its role in stent restenosis are still limited. We investigated the effect of preprocedural CD40 ligand (sCD40L) on stent restenosis. We enrolled 36 patients (mean age 61.4 +/- 8.5 years) with stable angina who underwent successful stent implantation. Control angiograms were performed in all patients after 6 months. Plasma sCD40L and high-sensitive C-reactive protein levels were measured before stent implantation and at 1 and 6 months after the procedure. Angiographically proven restenosis rate was 27.8%. Plasma sCD40L levels were significantly higher (preprocedural 0.74 +/- 0.79) and more prolonged in patients with stent restenosis compared with patients without stent restenosis (0.02 +/- 0.22 ng/ml, p < 0.001). According to receiver-operator characteristic analysis, sCD40L > 0.41 ng/ml was the best distinguished parameter between patients with and without restenosis. At the multivariate logistic regression analysis, preprocedural sCD40L was an independent predictor (RR 39.4, 95% confidence interval 4.05 to 383.8, p = 0.002) of stent restenosis after adjusting for confounding variables, including diabetes, reference vessel diameter, lesion length, stent diameter, stent length, and baseline high-sensitive C-reactive protein. Sensitivity, specificity, and positive and negative predictive values and likelihood ratio of preprocedural sCD40L levels in stent restenosis were 78%, 92%, 78%, 92%, and 9.37%, respectively. In conclusion, enhanced inflammation of plaque (increased sCD40L) before percutaneous coronary intervention may increase the rate of stent restenosis. Increased preprocedural sCD40L level is an independent predictor of stent restenosis. We can use this marker for the assessment of risk stratification before planning stent implantation.
CD40与CD40配体的相互作用参与动脉粥样硬化的炎症发病机制,但关于其在支架再狭窄中作用的临床数据仍然有限。我们研究了术前CD40配体(sCD40L)对支架再狭窄的影响。我们纳入了36例(平均年龄61.4±8.5岁)稳定型心绞痛患者,这些患者成功接受了支架植入术。所有患者在6个月后进行对照血管造影。在支架植入术前、术后1个月和6个月测量血浆sCD40L和高敏C反应蛋白水平。血管造影证实的再狭窄率为27.8%。与无支架再狭窄的患者相比,有支架再狭窄的患者血浆sCD40L水平显著更高(术前为0.74±0.79)且持续时间更长(0.02±0.22 ng/ml,p<0.001)。根据受试者工作特征分析,sCD40L>0.41 ng/ml是区分有再狭窄和无再狭窄患者的最佳参数。在多因素逻辑回归分析中,在调整包括糖尿病、参考血管直径、病变长度、支架直径、支架长度和基线高敏C反应蛋白等混杂变量后,术前sCD40L是支架再狭窄的独立预测因子(相对风险39.4,95%置信区间4.05至383.8,p = 0.002)。术前sCD40L水平在支架再狭窄中的敏感性、特异性、阳性和阴性预测值以及似然比分别为78%、92%、78%、92%和9.37%。总之,经皮冠状动脉介入治疗前斑块炎症增强(sCD40L升高)可能增加支架再狭窄率。术前sCD40L水平升高是支架再狭窄的独立预测因子。我们可以在计划支架植入前使用该标志物进行风险分层评估。